Univ. Prof. Dr. Erich Minar - Angiologie, Wien - Publikationen

..über 380 Veröffentlichungen, zum Beispiel:

  • 360. Minar E. DRUG ELUTING STENTS ABOVE THE KNEE J Cardiovasc Surg 2011;52(2):225-9. IF 1.35
  • 361. Amighi J, Hoke M, Mlekusch W, Schlager O, Exner M, Haumer M, Pernicka E, Koppensteiner R, Minar E, Rumpold H, Schillinger M, Wagner O. BETA 2 MICROGLOBULIN AND THE RISK FOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ASYMPTOMATIC CAROTID ATHEROSCLEROSIS Stroke. 2011 ;42:1826-33 IF 5.75 362. Kopp CW, Gremmel T, Steiner S, Seidinger D, Minar E, Maurer G, Huber K PLATELET-MONOCYTE CROSS TALK AND TISSUE FACTOR EXPRESSION IN STABLE ANGINA VS. UNSTABLE ANGINA/NON ST-ELEVATION MYOCARDIAL INFARCTION Platelets. 2011; 22(7):530-6 IF 2.11
  • 363. Sixt S, Rastan A, Scheinert D, Krankenberg H, Steinkamp H, Schmidt A, Sievert H, Minar E, Bosiers M, Peeters P, Balzer JO, Tübler T, Wissgott C, Carpio Cancino OG, Schwarzwalder U, Zeller T. THE 1-YEAR CLINICAL IMPACT OF ROTATIONAL ASPIRATION ATHERECTOMY OF INFRAINGUINAL LESIONS. Angiology. 2011; 62(8):645-56 IF 1.0 364. Hoke M, Schillinger M, Dick P, Exner M, Koppensteiner R, Minar E, Mlekusch W, Schlager O, Wagner O, Mannhalter C. POLYMORPHISM OF THE PALLADIN GENE AND CARDIOVASCULAR OUTCOME IN PATIENTS WITH ATHEROSCLEROSIS. Eur J Clin Invest. 2011;41(4):365-71 IF 2.73 365. Sixt S, Scheinert D, Rastan A, Krankenberg H, Steinkamp H, Schmidt A, Sievert H, Minar E, Bosiers M, Peeters P, Balzer JO, Tübler T, Wissgott C, Nielsen C, Schwarzwälder U, Zeller T. ONE-YEAR OUTCOME AFTER PERCUTANEOUS ROTATIONAL AND ASPIRATION ATHERECTOMY IN INFRAINGUINAL ARTERIES IN PATIENT WITH AND WITHOUT TYPE 2 DIABETES MELLITUS. Ann Vasc Surg. 2011 ;25(4):520-9. IF 1.33
  • 366. Langenberger H, Schillinger M, Plank C, Sabeti S, Dick P, Cejna M, Lammer J, Minar E, Loewe C. AGREEMENT OF DUPLEX ULTRASONOGRAPHY VS. COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR EVALUATION OF NATIVE AND IN- STENT SFA RE-STENOSIS-FINDINGS FROM A RANDOMIZED CONTROLLED TRIAL Eur J Radiol. 2011 Jun 22. [Epub ahead of print] IF 2.94
  • 367. M. Schillinger, E.Minar. CLAUDICATION: TREATMENT OPTIONS FOR FEMOROPOPLITEAL DISEASE Progress in Cardiovascular Diseases 2011;54: 41–46 IF 4.85
  • 368. Hoke M, Schillinger M, Zorn G, Wonnerth A, Amighi J, Mlekusch W, Speidl W, Maurer G, Koppensteiner R, Minar E, Wojta J, Niessner A.. THE PROGNOSTIC IMPACT OF SOLUBLE APOPTOSIS-STIMULATING FRAGMENT ON MORTALITY IN PATIENTS WITH CAROTID ATHEROSCLEROSIS Stroke 2011;42:2465-70 IF 5.75
  • 369. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T ESC GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF PERIPHERAL ARTERY DISEASES: DOCUMENT COVERING ATHEROSCLEROTIC DISEASE OF EXTRACRANIAL CAROTID AND VERTEBRAL, MESENTERIC, RENAL, UPPER AND LOWER EXTREMITY ARTERIES Eur Heart J. 2011; 32:2851-906 IF 10.05
  • 370. RE-NOVATE II Study Group ( Collaborator: E.Minar) ORAL DABIGATRAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER PRIMARY TOTAL HIP ARTHROPLASTY (RE-NOVATE II). A RANDOMISED, DOUBLE- BLIND, NON-INFERIORITY TRIAL. Thromb Haemost 2011; 105:721-9 IF 4.70 371. Hoke M, Schillinger T, Mlekusch W, Wagner O, Minar E, Schillinger M. THE IMPACT OF DENTAL DISEASE ON MORTALITY IN PATIENTS WITH ASYMPTOMATIC CAROTID ATHEROSCLEROSIS. Swiss Med Wkly. 2011; 141:w13236 IF 1.82 372. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI;
  • 373. Hoke M, Pernicka E, Niessner A, Goliasch G, Amighi J, Koppensteiner R, Minar E, Mlekusch W, Rumpold H, Wagner O, Schillinger M. RENAL FUNCTION AND LONG-TERM MORTALITY IN PATIENTS WITH ASYMPTOMATIC CAROTID
    ATHEROSCLEROSIS Thromb Haemost. 2012;107: 150-57 IF 4.70 374 . Bergqvist D, Arcelus JI, Felicissimo P; ETHOS investigators. EVALUATION OF THE DURATION OF THROMBOEMBOLIC PROPHYLAXIS AFTER HIGH-RISK ORTHOPAEDIC SURGERY: THE ETHOS OBSERVATIONAL STUDY. Thromb Haemost. 2012;;107(2):280-7. IF 4.70
  • 375. Bergqvist D, Arcelus JI, Felicissimo P; ETHOS investigators. POST-DISCHARGE COMPLIANCE TO VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HIGH- RISK ORTHOPAEDIC SURGERY: RESULTS FROM THE ETHOS REGISTRY. Thromb Haemost. 2012; 107(2):280-7. IF 4.70
  • 379. Minar E. SHOULD I PREFER CHEST PAIN OVER LEG PAIN? Vasa 2012; 41 (2): 75-77 (Editorial) IF 1.31
  • 380. Minar E, Schillinger M: INNOVATIVE TECHNOLOGIES FOR SFA OCCLUSIONS: DRUG COATED BALLOONS IN SFA LESIONS. J Cardiovasc Surg 2012;53(4):481-6 IF 1.56 .
  • 381. Minar E. ENDOVASCULAR FIRST STRATEGY FOR ALL PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PAD) ? Interventional Cardiology 2012;4:393-395 (Editorial) 382. Goliasch G, Schillinger M, Mayer FJ, Wonnerth A, Koppensteiner R, Minar E, Maurer G, Niessner A, Hoke M. USEFULNESS OF HEMOGLOBIN LEVEL TO PREDICT LONG-TERM MORTALITY IN PATIENTS WITH ASYMPTOMATIC CAROTID NARROWING BY ULTRASONOGRAPHY Am J Cardiol. 2012 Aug 23. [Epub ahead of print IF 3.37 383. Minar E. RESUSCITATION OF ENDOVASCULAR BRACHYTHERAPY OWING TO IMPROVED LOGISTICS (COMMENTARY) J Endovasc Ther 2012 ; 19(4):476-9 IF 2.86
  • 384. Schillinger M, Minar E. PERCUTANEOUS TREATMENT OF PERIPHERAL ARTERY DISEASE: NOVEL TECHNIQUES. Circulation. 2012;126(20):2433-40 IF 14.74
  • 385. Hoke M, Ljubuncic E, Steinwender C, Huber K, Minar E, Koppensteiner R, Leisch F, Dick P, Kerschner K, Schillinger M, Hofmann R, Niessner A . A VALIDATED RISK SCORE TO PREDICT OUTCOMES AFTER CAROTID STENTING Circ Cardiovasc Interv. 2012;5: 50
  • 386. E.Minar: FEMORAL STENTING: WHAT DO THE GUIDELINES TELL US J Cardiovasc Surg 2013;
  • 387. Schulman et al for the RE-SONATE Trial Investigators. EXTENDED USE OF DABIGATRAN, WARFARIN, OR PLACEBO IN VENOUS THROMBOEMBOLISM N Engl J Med. 2013;368(8):709-18